* VolitionRX press release [https://seekingalpha.com/pr/20201938-volitionrx-limited-announces-second-quarter-2025-financial-results-and-business-update] (NYSE:VNRX [https://seekingalpha.com/symbol/VNRX]): Q2 Recorded just over $0.4 million revenue for the second quarter, bringing first half 2025 growth to 15% over the prior year.
* Net loss was down 11% for the quarter and 24% for the first half compared to the prior year comparatives.
* Net cash used in operating activities for the first half of 2025 was $10.6 million, down 30% over the same period prior year.
* Cash and cash equivalents as of June 30, 2025 totaled approximately $2.3 million compared to $3.3 million as of December 31, 2024.
* Subsequent to quarter end we received $1.2 million from a registered direct offering which included participation by some of our directors.
* Shares -2.14% AH.
MORE ON VOLITIONRX
* VolitionRX Limited (VNRX) Q1 2025 Earnings Call Transcript [https://seekingalpha.com/article/4787757-volitionrx-limited-vnrx-q1-2025-earnings-call-transcript]
* VolitionRx prices $1.2M registered direct offering [https://seekingalpha.com/news/4477897-volitionrx-prices-12m-registered-direct-offering]
* VolitionRX aims for cash flow neutrality in 2025 as human diagnostics licensing advances [https://seekingalpha.com/news/4449843-volitionrx-aims-for-cash-flow-neutrality-in-2025-as-human-diagnostics-licensing-advances]
* Seeking Alpha’s Quant Rating on VolitionRX [https://seekingalpha.com/symbol/VNRX/ratings/quant-ratings]
* Historical earnings data for VolitionRX [https://seekingalpha.com/symbol/VNRX/earnings]
VolitionRX reports Q2 results
Published 2 months ago
Aug 14, 2025 at 9:07 PM
Positive
Auto